166 related articles for article (PubMed ID: 38104484)
1. M
Liu X; Li P; Huang Y; Li H; Liu X; Du Y; Lin X; Chen D; Liu H; Zhou Y
Redox Biol; 2024 Feb; 69():102993. PubMed ID: 38104484
[TBL] [Abstract][Full Text] [Related]
2. Identification of a novel mechanism for reversal of doxorubicin-induced chemotherapy resistance by TXNIP in triple-negative breast cancer via promoting reactive oxygen-mediated DNA damage.
Chen Y; Feng X; Yuan Y; Jiang J; Zhang P; Zhang B
Cell Death Dis; 2022 Apr; 13(4):338. PubMed ID: 35414060
[TBL] [Abstract][Full Text] [Related]
3. ALKBH5-Mediated m6A Demethylation of GLUT4 mRNA Promotes Glycolysis and Resistance to HER2-Targeted Therapy in Breast Cancer.
Liu H; Lyu H; Jiang G; Chen D; Ruan S; Liu S; Zhou L; Yang M; Zeng S; He Z; Wang H; Li H; Zheng G; Liu B
Cancer Res; 2022 Nov; 82(21):3974-3986. PubMed ID: 36069931
[TBL] [Abstract][Full Text] [Related]
4. ALKBH5-mediated m6A-demethylation of USP1 regulated T-cell acute lymphoblastic leukemia cell glucocorticoid resistance by Aurora B.
Gong H; Liu L; Cui L; Ma H; Shen L
Mol Carcinog; 2021 Sep; 60(9):644-657. PubMed ID: 34169564
[TBL] [Abstract][Full Text] [Related]
5. Post-translational modification of RNA m6A demethylase ALKBH5 regulates ROS-induced DNA damage response.
Yu F; Wei J; Cui X; Yu C; Ni W; Bungert J; Wu L; He C; Qian Z
Nucleic Acids Res; 2021 Jun; 49(10):5779-5797. PubMed ID: 34048572
[TBL] [Abstract][Full Text] [Related]
6. Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066.
Cheng CC; Shi LH; Wang XJ; Wang SX; Wan XQ; Liu SR; Wang YF; Lu Z; Wang LH; Ding Y
Int J Oncol; 2018 Jul; 53(1):339-348. PubMed ID: 29750424
[TBL] [Abstract][Full Text] [Related]
7. METTL3 and ALKBH5 oppositely regulate m
Song H; Feng X; Zhang H; Luo Y; Huang J; Lin M; Jin J; Ding X; Wu S; Huang H; Yu T; Zhang M; Hong H; Yao S; Zhao Y; Zhang Z
Autophagy; 2019 Aug; 15(8):1419-1437. PubMed ID: 30870073
[TBL] [Abstract][Full Text] [Related]
8. DDX3 modulates cisplatin resistance in OSCC through ALKBH5-mediated m
Shriwas O; Priyadarshini M; Samal SK; Rath R; Panda S; Das Majumdar SK; Muduly DK; Botlagunta M; Dash R
Apoptosis; 2020 Apr; 25(3-4):233-246. PubMed ID: 31974865
[TBL] [Abstract][Full Text] [Related]
9. m
Nagaki Y; Motoyama S; Yamaguchi T; Hoshizaki M; Sato Y; Sato T; Koizumi Y; Wakita A; Kawakita Y; Imai K; Nanjo H; Watanabe H; Imai Y; Minamiya Y; Kuba K
Genes Cells; 2020 Aug; 25(8):547-561. PubMed ID: 32449584
[TBL] [Abstract][Full Text] [Related]
10. ALKBH5-mediated m
Hao L; Yin J; Yang H; Li C; Zhu L; Liu L; Zhong J
Aging (Albany NY); 2021 Jan; 13(3):4045-4062. PubMed ID: 33428593
[TBL] [Abstract][Full Text] [Related]
11. Bioactive peptide inhibits acute myeloid leukemia cell proliferation by downregulating ALKBH5-mediated m
Zhang L; Su X
Cell Oncol (Dordr); 2022 Jun; 45(3):355-365. PubMed ID: 35579750
[TBL] [Abstract][Full Text] [Related]
12. N6-methyladenosine demethylase ALKBH5 suppresses colorectal cancer progression potentially by decreasing PHF20 mRNA methylation.
Zhang Z; Wang L; Zhao L; Wang Q; Yang C; Zhang M; Wang B; Jiang K; Ye Y; Wang S; Shen Z
Clin Transl Med; 2022 Aug; 12(8):e940. PubMed ID: 35979628
[TBL] [Abstract][Full Text] [Related]
13. Substance P Receptor Signaling Mediates Doxorubicin-Induced Cardiomyocyte Apoptosis and Triple-Negative Breast Cancer Chemoresistance.
Robinson P; Kasembeli M; Bharadwaj U; Engineer N; Eckols KT; Tweardy DJ
Biomed Res Int; 2016; 2016():1959270. PubMed ID: 26981525
[TBL] [Abstract][Full Text] [Related]
14. ALKBH5 Promotes Multiple Myeloma Tumorigenicity through inducing m
Yu T; Yao L; Yin H; Teng Y; Hong M; Wu Q
Int J Biol Sci; 2022; 18(6):2235-2248. PubMed ID: 35414790
[TBL] [Abstract][Full Text] [Related]
15. ALKBH5 regulates paclitaxel resistance in NSCLC via inhibiting CEMIP-mediated EMT.
Gao L; Qiao L; Li Y; Jia L; Cui W; Yang J; Wu C; Wang L
Toxicol Appl Pharmacol; 2024 Feb; 483():116807. PubMed ID: 38199493
[TBL] [Abstract][Full Text] [Related]
16. N
Zhu Z; Qian Q; Zhao X; Ma L; Chen P
Gene; 2020 Mar; 731():144348. PubMed ID: 31927006
[TBL] [Abstract][Full Text] [Related]
17. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
[TBL] [Abstract][Full Text] [Related]
18. Promoting axon regeneration by inhibiting RNA N6-methyladenosine demethylase ALKBH5.
Wang D; Zheng T; Zhou S; Liu M; Liu Y; Gu X; Mao S; Yu B
Elife; 2023 Aug; 12():. PubMed ID: 37535403
[TBL] [Abstract][Full Text] [Related]
19. RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential.
Qu J; Yan H; Hou Y; Cao W; Liu Y; Zhang E; He J; Cai Z
J Hematol Oncol; 2022 Jan; 15(1):8. PubMed ID: 35063010
[TBL] [Abstract][Full Text] [Related]
20. EGFR promotes ALKBH5 nuclear retention to attenuate N6-methyladenosine and protect against ferroptosis in glioblastoma.
Lv D; Zhong C; Dixit D; Yang K; Wu Q; Godugu B; Prager BC; Zhao G; Wang X; Xie Q; Bao S; He C; Heiland DH; Rosenfeld MG; Rich JN
Mol Cell; 2023 Dec; 83(23):4334-4351.e7. PubMed ID: 37979586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
